Glycomed Inc. preclinical data

The Alameda, Calif., company discussed its new compounds at the meeting of the American Chemical Society in Washington, saying that several of the selectin inhibitors are active in relevant animal models.

Using rational drug design, GLYC cut away unnecessary carbohydrate structures from sLeX, a complex sugar, showing that it can be replaced with simpler molecules, such as acetic acid or a group bearing a carboxylic acid. ...